{
    "clinical_study": {
        "@rank": "141134", 
        "acronym": "CLEAR", 
        "arm_group": {
            "arm_group_label": "Lenalidomide and CC-292", 
            "arm_group_type": "Experimental", 
            "description": "Combination of lenalidomide and CC-292."
        }, 
        "brief_summary": {
            "textblock": "This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy\n      and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292\n      and lenalidomide combination therapy.  Subjects will be followed for disease progression and\n      collection of second primary malignancy (SPM) events. This dose escalation will be followed\n      by an exploratory expansion phase in 3 cohorts of 12 patients each."
        }, 
        "brief_title": "A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed/Refractory B-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histology:\n\n               1. Patients with any type of B-cell Lymphoma except CLL, SLL and Waldenstr\u00f6m\n                  disease will be eligible during the dose escalation phase\n\n               2. During the expansion phases, patients with DLBCL for cohort A, mantle cell\n                  lymphoma for cohort B and any other type of B-cell lymphoma except CLL, SLL and\n                  Waldenstr\u00f6m disease for cohort C.\n\n          -  Other criteria:\n\n               -  Signed inform consent\n\n               -  Patients should be relapsed or refractory NHL after \u22651 prior\n                  Rituximab-containing regimen for which no other type of therapy is of higher\n                  priority\n\n               -  Aged 18 years or more.\n\n               -  ECOG performance status 0-2.\n\n               -  Measurable disease defined by at least one single node or tumor lesion > 1.5 cm.\n\n               -  Life expectancy of \u2265 90 days (3 months).\n\n               -  Patients must be eligible and willing to undergo excisional biopsies of tumor\n                  sites with a lymph node of minimum 1 cm at baseline and after 21 days of\n                  treatment\n\n               -  Females of childbearing potential (FCBP)\u2020 must have two negative serum or urine\n                  pregnancy tests with a sensitivity of at least 25 mIU/mL before starting\n                  lenalidomide - the first test must be performed within 10-14 days before\n                  starting lenalidomide treatment and the second test must be performed within 24\n                  hours before starting lenalidomide\n\n               -  FCBP must either commit to continued abstinence from heterosexual intercourse or\n                  begin two methods of birth control, at least 4 weeks before she starts taking\n                  lenalidomide.  FCBP must also agree to monthly pregnancy testing and must be\n                  counseled at a minimum of every 4 weeks about pregnancy precautions and risks of\n                  fetal exposure.\n\n               -  Men must agree not to father a child and agree to use a condom if his partner is\n                  of child bearing potential.  Men must also be counseled at a minimum of every 4\n                  weeks about pregnancy precautions and risks of fetal exposure.\n\n        Exclusion Criteria:\n\n        Previous treatment with lenalidomide or a BTK inhibitor. Central nervous system or\n        meningeal involvement. Contraindication to any drug contained in this regimen Concomitant\n        use of medicines known to cause QT prolongation or torsades de pointes HIV disease, active\n        hepatitis B or C. Any serious active disease or co-morbid medical condition (according to\n        investigator's decision);\n\n        Any of the following laboratory abnormalities :\n\n          -  Absolute neutrophil count (ANC) < 1,500 cells/mm3 (1.5 x 109/L).\n\n          -  Platelet count < 80,000/mm3 (80 x 109/L)\n\n          -  Serum SGOT/AST or SGPT/ALT >3.0 x upper limit of normal (ULN).\n\n          -  Serum total bilirubin > 1.5 ULN except in case of hemolytic anemia and Gilbert's\n             syndrome.\n\n        Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of < 50 mL /min Prior\n        history of malignancies other than lymphoma (except for basal cell or squamous cell\n        carcinoma of the skin or carcinoma in situ of the cervix or breast or Incidental\n        histological finding of prostate cancer [TNM stage of T1a or T1b]) unless the subject has\n        been free of the disease for \u2265 5 years Any serious medical condition, laboratory\n        abnormality, or psychiatric illnessthat would prevent the subject from signing the\n        informed consent form.\n\n        Pregnant or lactating females. Prior \u2265 Grade 3 allergic reaction/hypersensitivity to\n        thalidomide and/or pomalidomide.\n\n        Prior \u2265 Grade 3 rash or any desquamating (blistering) rash while taking thalidomide and/or\n        pomalidomide.\n\n        Subjects with \u2265 Grade 2 neuropathy. Use of any standard or experimental anti-cancer drug\n        therapy within 28 days of the initiation (Day 1) of study drug therapy.\n\n        Chronic use of proton pump inhibitors, H2 antagonists or antacids or their use in the last\n        7 days prior to the first CC-292 dose. Patients with chronic gastroesophageal reflux\n        disease, dyspepsia, and peptic ulcer disease, should be carefully evaluated for their\n        suitability for this treatment prior to enrollment in this study. These medications should\n        be avoided throughout the study.\n\n        Patients taking corticosteroids during the 4 weeks prior to inclusion, unless administered\n        at a dose equivalent of \u2264 10 mg/day prednisone (over these 4 weeks)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766583", 
            "org_study_id": "CLEAR"
        }, 
        "intervention": {
            "arm_group_label": "Lenalidomide and CC-292", 
            "description": "CC-292 + lenalidomide", 
            "intervention_name": "CC-292 + lenalidomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Lenalidomide", 
                "Thalidomide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Open label, 3 + 3 dose escalation study followed by an expansion phase.", 
        "lastchanged_date": "February 12, 2014", 
        "link": {
            "description": "LYSA (the Lymphoma Study Association)", 
            "url": "http://www.lysa-lymphoma.org/"
        }, 
        "location": [
            {
                "contact": {
                    "email": "corinne.haioun@hmn.aphp.fr", 
                    "last_name": "Corinne Haioun, PhD", 
                    "phone": "+331 49 81 41 54"
                }, 
                "facility": {
                    "address": {
                        "city": "Cr\u00e9teil", 
                        "country": "France", 
                        "zip": "94010"
                    }, 
                    "name": "Hopital henri mondor"
                }, 
                "investigator": [
                    {
                        "last_name": "Corinne Haioun, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Karim Belhadj, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jehan Dupuis, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Isabelle Gaillard, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "franck.morschhauser@chru-lille.fr", 
                    "last_name": "Franck Morschhauser, MD", 
                    "phone": "+333 20 44 57 13"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHU de Lille"
                }, 
                "investigator": [
                    {
                        "last_name": "Franck Morschhauser, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Louis Terriou, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sabine Tricot, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "BOUABDALLAHR@ipc.unicancer.fr", 
                    "last_name": "R\u00e9da Bouabdallah, MD", 
                    "phone": "+334 91 22 33 33"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Institut Paoli Calmette"
                }, 
                "investigator": [
                    {
                        "last_name": "R\u00e9da Bouabdallah, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Florence Broussais-Guillaumot, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Diane Coso, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jean-Marc SCHIANO DE COLELLA, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Steven Le Gouill, PhD", 
                    "phone": "+332 40 08 32 71"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU de Nantes"
                }, 
                "investigator": [
                    {
                        "last_name": "Steven Le Gouill, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Thomas Gastinne, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nicolas Blin, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Cyrille Touzeau, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Viviane DUBRUILLE, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "B\u00e9atrice Mahe, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Virginie ROLLAND, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Aline CLAVERT, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gilles.salles@chu-lyon.fr", 
                    "last_name": "Gilles Salles, PhD", 
                    "phone": "+334 78 86 43 01"
                }, 
                "facility": {
                    "address": {
                        "city": "Pierre B\u00e9nite", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "CHU Lyon Sud"
                }, 
                "investigator": [
                    {
                        "last_name": "Gilles Salles, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Bertrand Coiffier, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Fadhela Bouafia, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Daniel Espinouse, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lionel Karlin, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Laure Lebras, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Sophie Michallet, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Catherine Traulle, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ysebaert.l@chu-toulouse.fr", 
                    "last_name": "Lo\u00efc Ysebaert, MD", 
                    "phone": "+335 61 77 20 78"
                }, 
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU de Toulouse"
                }, 
                "investigator": [
                    {
                        "last_name": "Lo\u00efc Ysebaert, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Lucie Oberic, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Murielle Roussel, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Benjamin Hebraud, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA", 
        "overall_contact": {
            "email": "elise.hutasse@lysarc.org", 
            "last_name": "Elise HUTASSE", 
            "phone": "+33472669333"
        }, 
        "overall_contact_backup": {
            "email": "yvain.robreau@lysarc.org", 
            "last_name": "Yvain Robreau", 
            "phone": "+33472669333"
        }, 
        "overall_official": [
            {
                "affiliation": "CHU Lyon - Sud - LYSA", 
                "last_name": "Gilles Salles, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CHU de Toulouse  LYSA", 
                "last_name": "Lo\u00efc YSEBAERT, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The optimal CC-292 and lenalidomide combination will be determined based on the maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and/or the analysis of adverse events, serious adverse events and toxicities observed during the study", 
            "measure": "Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall response rate and overall response rate, complete and partial response rates, progression free survival, response duration, time to next treatment and overall survival", 
                "measure": "preliminary efficacy signals of the CC-292 + Lenalidomide combination", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Observed maximum plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8 hours post dose"
            }, 
            {
                "measure": "time to reach maximum observed plasma concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8 hours post dose"
            }, 
            {
                "measure": "Terminal phase rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8 hours post dose"
            }, 
            {
                "measure": "plasma decay half-life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8 hours post dose"
            }, 
            {
                "description": "Area under the plasma concentration versus time curve from time zero (predose) to time of the last quantifiable concentration (0-t)", 
                "measure": "Area under the curve from time zero to the last quantifiable concentration [AUC(0-t)]", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8 hours post dose"
            }, 
            {
                "description": "Area under the plasma concentration versus time curve (AUC) from time zero (predose)to extrapolated infinity(0-\u221e)", 
                "measure": "Area under the curve from time zero to extrapolated infinity [AUC(0-\u221e)]", 
                "safety_issue": "No", 
                "time_frame": "0, 0.5, 1, 2, 4, 6, 8 hours post dose"
            }, 
            {
                "description": "BTK receptor occupancy will be determined in the peripheral blood cells and tumor tissue", 
                "measure": "BTk receptor occupancy", 
                "safety_issue": "No", 
                "time_frame": "0 (predose) and 21 days post dose"
            }
        ], 
        "source": "The Lymphoma Academic Research Organisation", 
        "sponsors": {
            "collaborator": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Lymphoma Academic Research Organisation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}